Results of a study of 169 patients suffering from pancreatic islet cell tumors were presented at the World Congress on Gastrointestinal Cancer. Participants were randomized and either received 37.5mg/day of Sutent [sunitinib] or placebo. All participants had progressed over the previous 12 months and were receiving the best care. According to results patients treated with Pfizer"s drug, Sutent, had a median progression free result of 11.1 months compared to 5.5 months if receiving placebo. No major safety concerns were reported and most commonly reported adverse events were neutropenia, hypertension, abdominal pain, diarrhea, hyperglycemia and hand-foot syndrome.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지